Mechano growth factor FAQ: common questions answered
A muscle-repair peptide idea with mixed lab findings and no human dosing studies.
Also called: MGF, Non-PEG MGF, MGF E peptide, MGF-Ct24E, IGF-1Ec E-domain peptide.
IGF-1 splice variants · Synthetic E-domain peptide associated with IGF-1Ec · Evidence: Animal studies only.
- Is Mechano growth factor (MGF) FDA-approved? No approved product, label or indication found. Category 3 is an inadequate-nomination finding, not a demonstrated safety finding.
- How do people take it? Into muscle, after workouts; days per week not stated. Source: reported by users, not an established dose.
- What's the difference between Mechano growth factor (MGF) and IGF-1 LR3? Mechano growth factor (MGF): a muscle-repair peptide idea with mixed lab findings and no human dosing studies. IGF-1 LR3: an unapproved growth signal with no human trials found. Why people pair them: users combine or alternate peptides for hoped-for muscle growth. Timing advice conflicts.
- Can I take it with IGF-1 LR3? Users combine or alternate peptides for hoped-for muscle growth. Timing advice conflicts. No human combination study was found. Added harms and effective exposure are unknown. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). MGFs are named. S2 also covers substances with similar structure or effects, including PEGylated analogues.
- How long does a mixed vial last? No validated storage temperature or usable lifetime after mixing was found. Clear appearance does not prove sterility.
Related to Mechano growth factor (MGF)
- PEG-MGF: A modified MGF peptide with no human dosing studies and uncertain identity in unregulated vials.
- IGF-1 LR3: An unapproved growth signal with no human trials found.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- Anaphylaxis: MedlinePlus Medical Encyclopedia, MedlinePlus · MedlinePlus
- Low Blood Glucose (Hypoglycemia), National Institute of Diabetes and Digestive and Kidney Diseases
- Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise., Hameed M et al. · The Journal of physiology · 2003
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration., Dominikowski A et al. · Frontiers in endocrinology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.